eFoodSafety.com (OTCBB: EFSF, www.efoodsafety.com), a researcher, developer, and marketer of whole food nutraceutical products, has launched an all-natural supplement, called Cinnechol™ (www.cinnechol.com), that offers a complementary and/or alternative solution to traditional cholesterol drugs. Cinnechol is designed to reduce total cholesterol levels, LDL (“bad”) cholesterol, and triglycerides without adverse side effects while enhancing overall cardiovascular health. The product has also been shown to improve levels of HDL (“good”) cholesterol.
On Sunday, March 30, 2008, the New England Journal of Medicine published results that the prescription cholesterol drug Vytorin, has illustrated no benefit for reducing the accumulation of fatty plaque in the arteries. Millions of Americans have taken the drug, or one of its components, Zetia, since its introduction to the market in 2004, racking up $5 billion in sales despite limited proof of results. News of the drug’s failure has caused a stir in the medical community and left consumers confused and angered about the effectiveness and safety of prescription “blockbuster” drugs.
A study* conducted by the National Center for Complementary and Alternative Medicine (NCCAM) and the Center for Disease Control’s National Center for Health Statistics shows that approximately 36% of U.S. adults ages eighteen and older use some form of complementary and alternative medicine (CAM), with 18.9% of those using various natural products. (The study defines CAM as a group of diverse medical and health care systems, therapies, and products that are not presently considered conventional medicine.)
eFoodSafety recently announced that it has launched national direct-response commercials to introduce Cinnechol™ to a broad audience with potential viewership in the millions. The Company is cautiously optimistic that the campaign will significantly increase market exposure, brand recognition, and revenue.
“We are delighted to introduce Cinnechol™ to consumers and help educate them about the benefits of our natural solution to high levels of LDL cholesterol,” says Patricia Gruden, CEO of eFoodSafety. “It appears that Americans are becoming savvier about and more receptive toward choosing all-natural treatment options for common health conditions. We believe that our whole food products such as Cinnechol™ provide tremendous value by increasing the scope of options available to them.”
*Source: Barnes P, Powell-Griner E, McFann K, Nahin R. CDC Advance Data Report #343. Complementary and Alternative Medicine Use Among Adults: United States, 2002. May 27, 2004.
About eFoodSafety.com
eFoodSafety.com, Inc., based in Scottsdale, Arizona, is dedicated to improving health conditions around the world through its innovative technologies. The Company’s Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin™ (formerly named Big Six Plus) – EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte™ product, which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture, is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research.
The Company’s Cinnergen™ is a clinically-researched, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism, is available for sale at (www.cinnergendirect.com) and through national retailers; its Cinnechol™ (www.cinnechol.com) is a multi-faceted nutritional supplement specifically designed to naturally promote reduction in total cholesterol levels without causing any side effects, as well as enhance overall cardiovascular health. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system.
The Company’s iBoost, Inc. subsidiary is the distributor of the Immune Boost Bar™, a non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient product that helps fortify the body’s immune system. The product contains Citroxin O2™, eFoodSafety’s proprietary all natural supplement proven effective in fighting several types of harmful bacteria, and forty active compounds that assist with enhancing immunity, detoxification, cleansing, and metabolic efficiency. The Immune Boost Bar™ is available in four delicious flavors: chocolate, oatmeal-raisin, chocolate mint and peanut butter and can be purchased at www.immuneboost.com.
The Company’s MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the owner of the Talsyn™-CI/bid Scar Cream, a product that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn™ line.
Please visit the Company’s website at: http://www.efoodsafety.com.
Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are “forward-looking statements.” Such forward-looking statements are sometimes identified by words such as “intends,” “anticipates,”“believes,” “expects,” and “hopes.” The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Contacts:
Jens Dalsgaard, 415-884-0348
or
The
Investor Relations Group
212-825-3210
or
Investor
Relations:
Michael Crawford
mcrawford@investorrelationsgroup.com
or
Brett
Foley
bfoley@investorrelationsgroup.com
or
Emily
Hanan
ehanan@investorrelationsgroup.com
or
Media
Relations:
Susan Morgenbesser
smorgenbesser@investorrelationsgroup.com
